**Result**:
- Number:
    - Indacaterol+tiotropium: 570
    - Placebo+tiotropium: 561
- Differences between indacaterol+tio vs. tio+placebo
    - FEV1 AUC 5 min~8 h:
        - moderate: 120 mL (90~160)
        - severe: 130 mL (100~160)
    - Smoking status:
        - ex smoker: 120 mL (90~150)
        - current smoker: 130 mL (100~170)
    - ICS use - non-users: 120 mL (90~160)
- Trough FEV1: Indacaterol+tiotropium: 130 mL (100~160)
- COPD severity:
    - moderate: Indacaterol+tiotropium: 90 mL (50~130), Placebo+tiotropium: 70 mL (30~110)
    - severe: Indacaterol+tiotropium: 70 mL (30~110), Placebo+tiotropium: 70 mL (40~110)
- Smoking status:
    - ex smoker: Indacaterol+tiotropium: 80 mL (40~130), Placebo+tiotropium: 80 mL (40~130)
    - current smoker: Indacaterol+tiotropium: 70 mL (30~110), Placebo+tiotropium: 80 mL (50~120)
- ICS use:
    - non-users: Indacaterol+tiotropium: 80 mL (50~120), Placebo+tiotropium: 70 mL (30~110)
    - users: Indacaterol+tiotropium: 80 mL (50~120), Placebo+tiotropium: [not available]
- Patient reported symptoms and use of as-needed salbutamol:
    - Change from baseline symptom score (full 24 h): Indacaterol+tiotropium: -2.1 (0.20), Placebo+tiotropium: -1.6 (0.21)
    - Change from baseline symptom score (day-time): Indacaterol+tiotropium: -1.2 (0.10), Placebo+tiotropium: -0.9 (0.10)
    - Change from baseline symptom score (night-time): Indacaterol+tiotropium: -1.0 (0.10), Placebo+tiotropium: -0.8 (0.10)
    - Change from baseline salbutamol use (puff/day): Indacaterol+tiotropium: -2.5 (0.17), Placebo+tiotropium: -1.3 (0.17)
    - Days during treatment with no salbutamol use (%): Indacaterol+tiotropium: 43.2 (1.91), Placebo+tiotropium: 34.2 (1.93)
- Adverse events (%):
    - Cough: Indacaterol+tiotropium: 10.4, Placebo+tiotropium: 3.7
    - Muscle spasm: Indacaterol+tiotropium: 2.3, Placebo+tiotropium: 0
    - Plasma potassium <3,5 mmol/L: Indacaterol+tiotropium: 2.3, Placebo+tiotropium: 2.1
    - Systolic BP-high: Indacaterol+tiotropium: 2.3, Placebo+tiotropium: 0.5
    - QTc interval (absolute value): Indacaterol+tiotropium: 3.2, Placebo+tiotropium: 2.9

\*post-salbutamol for FEV1 % and FEV1/FVC and pre/post salbutamol for reversibility

**Author, year publication**: Donald A Mahler et al., 2012
**Title**: Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison
**Country**: Study 1: 186 centers in 14 countries
**Setting/Design**: Double-blind tiotropium 18 µg+Indacaterol 150 µg once daily vs. tiotropium 18 µg+placebo
**Time frame**: 12-week study
**Randomization method**: An automated interactive voice response system and was stratified by COPD severity
**Allocation concealment**: Yes (An automated interactive voice response system)
**Blinding**: The blinding of indacaterol and placebo continued until the study
- Participants: Yes
- Investigators: Yes
- Outcome assessors: Yes
**Intention-to-treat**: Yes
**Follow-up period**: 12-week
**Loss to follow-up**: 29/572 for indacaterol+tiotropium, 37/570 for tiotropium+placebo group

**ITT anlaysis**:
- Number:
    - Indacaterol+tiotropium: 572
    - Placebo+tiotropium: 570
- Age:
    - Indacaterol+tiotropium: 63.1±8.83
    - Placebo+tiotropium: 62.84±8.98
- Sex (M):
    - Indacaterol+tiotropium: 63%
    - Placebo+tiotropium: 68%
- Ethnicity (Caucasian):
    - Indacaterol+tiotropium: 77.8%
    - Placebo+tiotropium: 79.3%
- FEV1 %predicted (postBD)*:
    - Indacaterol+tiotropium: 48.6 (9.74)
    - Placebo+tiotropium: 48.6 (9.76)
- FEV1/FVC (postBD)*:
    - Indacaterol+tiotropium: 47.0 (10.21)
    - Placebo+tiotropium: 47.2 (9.53)
- FEV1 reversibility (%)*:
    - Indacaterol+tiotropium: 16.3 (15.85)
    - Placebo+tiotropium: 16.5 (16.27)

**Inclusion**:
- Aged ≥40 years
- A smoking history of ≥10 pack yrs
- A diagnosis of moderate-to-severe COPD (postbronchodilator 30≤FEV1<65, FEV1/FVC<0.7)

**Exclusion**:
- A history of asthma
- History of exacerbation within the previous 6weeks

**Intervention**:
- Indacaterol+tiotropium: Indacaterol 150 µg once daily, Tiotropium, 18 µg once daily
- Placebo+tiotropium: tiotropium, 18 µg once daily
<PAGE>109